Pierre Fabre, EORTC commence encorafenib/binimetinib Phase III melanoma trial
Source: Clinical Trials Arena, May 2022
Pierre Fabre and the European Organisation for Research and Treatment of Cancer (EORTC) have screened the first subject in the Phase III COLUMBUS-AD clinical trial of encorafenib (Braftovi) and binimetinib (Mektovi) in resected stage II BRAF-mutant melanoma patients.
An oral small-molecule inhibitor of MEK, binimetinib acts on key enzymes in the MAPK signalling pathway (RAS-RAF-MEK-ERK). Encorafenib is an oral small-molecule inhibitor of BRAF kinase.
Pierre Fabre holds exclusive rights for the development and marketing of Braftovi and Mektovi globally, excluding some markets.
READ THE ORIGINAL FULL ARTICLE